Related Experiment Videos
[Use of streptodecase in acute myocardial infarct]
Insights
This study introduces streptodecase as a novel fibrinolytic drug for acute myocardial infarction. It demonstrated favorable clinical effects and prolonged blood fibrinolysis activation in 12 patients.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Context:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Fibrinolytic therapy is crucial in the early management of AMI.
- Streptokinase has been a standard fibrinolytic agent, but its efficacy and side effect profile are areas for improvement.
Purpose:
- To evaluate the efficacy and safety of streptodecase as a novel fibrinolytic agent in patients with acute myocardial infarction.
- To assess the impact of streptodecase on clinical manifestations and blood fibrinolysis.
- To compare the potential advantages of streptodecase over streptokinase in AMI treatment.
Summary:
- Streptodecase was administered intravenously at a dose of 3,000,000 units once to 12 patients during the early hours of myocardial infarction.
- The study observed favorable clinical outcomes and a sustained activating effect on blood fibrinolysis.
- These findings suggest streptodecase is a promising therapeutic option for acute myocardial infarction.
Impact:
- This research establishes streptodecase as a potential new therapeutic option for acute myocardial infarction.
- The drug's ability to activate blood fibrinolysis offers a prolonged therapeutic effect.
- Further studies are warranted to confirm these advantages over existing treatments like streptokinase.
Abstract:
This if the first time in the world that streptodecase has been used as a fibrinolytic drug during the first hours of clinical manifestations of myocardial infarction in 12 patients. The drug was given once, intravenously in the dose of 3,000,000 units. Favourable action of the drug on the clinical manifestations of the disease and its prolonged activating effect on the blood fibrinolysis have been established. The advantages of streptodecase over streptokinase in the treatment of acute myocardial infarction are discussed.